Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy can make your skin more sensitive in some people. The most commonly reported skin-related effects include injection-site reactions and, less frequently, a general heightened sensitivity or itching across the skin. These effects are recognised in semaglutide's clinical profile, though they affect a minority of users and are usually mild. As a prescription-only medicine, Wegovy is only available following a clinical assessment by a prescriber who reviews your full health picture before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is: it can, though it is not among the most common complaints. Semaglutide (the active ingredient in Wegovy) acts on GLP-1 receptors found throughout the body, and immune-mediated skin reactions are a recognised, if infrequent, part of its side-effect profile. The NHS page on semaglutide lists itching (pruritus) and rash among the side effects that some patients experience, alongside the more widely reported gastrointestinal symptoms.
Skin sensitivity on Wegovy tends to show up in one of two ways. The first is localised: redness, warmth, or mild swelling at the injection site itself, a predictable immune response to a subcutaneous injection that usually settles within a day or two. The second, which prompts more questions from people starting treatment, is generalised: skin that feels tender or reactive to the touch in areas away from the injection point. This is less common and its mechanism is not fully established, though changes in blood flow and autonomic nervous system activity during rapid weight change have been proposed as contributing factors.
It is worth being honest here: if you are reading this because you have started Wegovy and your skin suddenly feels strange, that unease is understandable. Noticing unexpected physical changes during any new treatment is unsettling. Our dedicated guide to sensitive skin on Wegovy goes into more detail for people who want a fuller picture of what to expect. The good news is that in most cases these sensations are mild and self-limiting. If you use Wegovy and develop significant skin changes, the right first call is your prescriber, not a web search.
Most skin-related reports associated with semaglutide sit firmly in the mild category. Injection-site bruising and temporary itching around the site are the most frequently noted. Rotating the injection site between the abdomen, thigh and upper arm each week reduces the likelihood of localised reactions building up in one area; the patient information leaflet covers this technique in detail and is the definitive reference for injection advice.
Further down the frequency scale, some people report a diffuse skin sensitivity (sometimes described as skin sensitive to touch, tingling or a crawling sensation) that has no obvious localised cause. There are also rare reports of alopecia (hair thinning) during treatment, which may be linked to rapid caloric reduction rather than to semaglutide itself; this distinction matters because it points towards nutritional support as the relevant intervention. Our clinical team discusses nutrition alongside treatment for exactly this reason.
Symptoms that require prompt medical assessment are different in character: a widespread rash developing quickly, facial swelling, difficulty breathing or throat tightness could indicate a serious allergic reaction (anaphylaxis) and need emergency attention. A rash that does not settle, or skin symptoms that worsen after each new dose, should be reviewed by a prescriber before continuing treatment. Suspected side effects from any medicine can be reported directly through the MHRA's Yellow Card scheme, which also helps build the post-market safety record for newer medicines like Wegovy.
Wegovy follows a stepped titration: the starting dose is 0.25 mg weekly, rising through 0.5 mg, 1.0 mg and 1.7 mg to the standard maintenance dose of 2.4 mg, with a higher 7.2 mg option now also MHRA-approved for eligible adults. Skin sensitivity, like the GI side effects semaglutide is better known for, is most likely to appear or intensify at the point of a dose step upward. The body is adjusting to a higher level of drug exposure, and that adjustment period is real.
This dose-step pattern is one reason the titration schedule exists: giving the body time to adapt at each level before moving higher. If skin symptoms appear during or after a dose increase, noting when they started and whether they settle within a fortnight is useful information for your prescriber. People who experience persistent or uncomfortable skin sensitivity (sometimes described as skin that is sensitive to touch on semaglutide) may benefit from a slower titration or a temporary pause at the current dose, both of which are clinical decisions made with a prescriber rather than self-managed choices.
Cost concerns sometimes lead people to explore whether lower doses might be extended for longer. If you have questions about the cost of treatment alongside what is included in a private prescription, this page on Wegovy pricing in the UK covers the landscape honestly. The priority here, though, is matching the dose to your body's response, and that requires an ongoing clinical relationship, not a fixed-dose product purchase.
A few practical points are worth knowing. First, rule out the injection site: if the sensitivity is localised and appears within hours of an injection, try rotating to a different site next week and check that your injection technique matches the instructions in the leaflet. Injecting into scar tissue or areas of lipohypertrophy (hardened fat from repeated injections in the same spot) can provoke stronger local reactions.
Second, consider whether any new topical product (a new moisturiser, detergent or soap) coincides with the symptom. Semaglutide treatment is associated with changes in the skin barrier in some people, which may mean skin reacts more readily to products it previously tolerated. Fragrance-free, gentle formulations tend to suit sensitive skin better during this period.
Third, and most directly: talk to a prescriber. Whether your skin feels itchy, painful, or simply different, a prescriber can help you work out whether the symptom is treatment-related, dose-dependent, or something else worth investigating. If you have not yet started Wegovy and are trying to understand the full side-effect picture before you do, a free consultation with our clinical team is the right starting point. Questions about specific symptoms (including whether Wegovy can make your skin itch or whether it can make your skin hurt) can be raised directly with a prescriber who knows your health history, not answered in a generalised way online.
At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. A clinician reads your answers personally and considers your individual circumstances before any treatment is approved or continued. If skin sensitivity is something you are experiencing or are concerned about, that conversation starts with your free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.